T. Rowe Price Investment Management
RLAY icon

T. Rowe Price Investment Management’s Relay Therapeutics RLAY Stock Holding History

T. Rowe Price Investment Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-814,814
Closed -$8.97M – 655
2023
Q4 		$8.97M Sell
814,814
-1,448,546
-64% -$12.2M 0.01% 518
2023
Q3 		$19M Hold
2,263,360
– – 0.01% 482
2023
Q2 		$28.4M Buy
2,263,360
+41,780
+2% +$520K 0.02% 443
2023
Q1 		$36.6M Buy
2,221,580
+215,039
+11% +$3.86M 0.03% 406
2022
Q4 		$30M Buy
2,006,541
+194,938
+11% +$3.73M 0.02% 414
2022
Q3 		$40.5M Buy
+1,811,603
New +$39.8M 0.03% 372

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

T. Rowe Price Investment Management's RLAY Position: Q1 2024 in Review

T. Rowe Price Investment Management sold out of Relay Therapeutics (RLAY) in Q1 2024, closing a stake of 814,814 shares — an estimated $8.97M sold.

T. Rowe Price Investment Management first reported a position in RLAY in Q3 2022 and held it in 6 quarters. The position peaked at $40.5M in Q3 2022. 189 funds tracked by Wall St. Rank hold RLAY as of Q1 2024.

  • T. Rowe Price Investment Management reported no remaining Relay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 814,814 Relay Therapeutics shares in Q1 2024, an estimated $8.97M.
  • T. Rowe Price Investment Management first reported a position in Relay Therapeutics in Q3 2022 and held it in 6 quarters.
  • T. Rowe Price Investment Management's Relay Therapeutics position peaked at $40.5M in Q3 2022.
  • 189 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2024.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2024, filed 15 May 2024.